Wecome Pharmaceutical Co Ltd (300878) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.001x

Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.42 Million ≈ $-208.32K USD) by net assets (CN¥1.03 Billion ≈ $150.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Wecome Pharmaceutical Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Wecome Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wecome Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Wecome Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.

Wecome Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Sri Trang Agro-Industry Public Company Limited BK:STA-R	0.237x
Ardmore Shipping Corporation F:A61	0.041x
APAQ Technology Co Ltd TW:6449	0.048x
Ningbo Baosi Energy Equipment Co Ltd SHE:300441	0.024x
Leong Hup International Berhad KLSE:6633	0.031x
Fastighetsbolaget Emilshus AB ST:EMIL-B	0.019x
Zhejiang Noblelift Equip SHG:603611	0.154x
Jiahe Foods Industry Co. Ltd. SHG:605300	0.014x

Annual Cash Flow Conversion Efficiency for Wecome Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wecome Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Wecome Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.17 Billion ≈ $171.77 Million	CN¥-27.17 Million ≈ $-3.98 Million	-0.023x	-155.89%
2023-12-31	CN¥1.41 Billion ≈ $205.95 Million	CN¥58.29 Million ≈ $8.53 Million	0.041x	-60.11%
2022-12-31	CN¥1.41 Billion ≈ $206.55 Million	CN¥146.57 Million ≈ $21.45 Million	0.104x	+315.97%
2021-12-31	CN¥1.41 Billion ≈ $206.18 Million	CN¥-67.74 Million ≈ $-9.91 Million	-0.048x	-255.47%
2020-12-31	CN¥1.38 Billion ≈ $202.58 Million	CN¥42.81 Million ≈ $6.26 Million	0.031x	-85.74%
2019-12-31	CN¥519.84 Million ≈ $76.07 Million	CN¥112.76 Million ≈ $16.50 Million	0.217x	-19.08%
2018-12-31	CN¥393.83 Million ≈ $57.63 Million	CN¥105.57 Million ≈ $15.45 Million	0.268x	+182.87%
2017-12-31	CN¥306.05 Million ≈ $44.79 Million	CN¥29.00 Million ≈ $4.24 Million	0.095x	-80.04%
2016-12-31	CN¥210.90 Million ≈ $30.86 Million	CN¥100.15 Million ≈ $14.66 Million	0.475x	+108.41%
2015-12-31	CN¥130.04 Million ≈ $19.03 Million	CN¥29.63 Million ≈ $4.34 Million	0.228x	-61.26%
2014-12-31	CN¥78.22 Million ≈ $11.45 Million	CN¥46.01 Million ≈ $6.73 Million	0.588x	-22.24%
2013-12-31	CN¥34.35 Million ≈ $5.03 Million	CN¥25.98 Million ≈ $3.80 Million	0.756x	--

About Wecome Pharmaceutical Co Ltd

SHE:300878 China Biotechnology

Market Cap

$651.09 Million

CN¥4.45 Billion CNY

Market Cap Rank

#10844 Global

#2935 in China

Share Price

CN¥30.73

Change (1 day)

+5.35%

52-Week Range

CN¥20.49 - CN¥39.45

All Time High

CN¥52.21